NVCRNMSHealthcare·Medical Devices#35 in industry

NovoCure Limited

Reports in 3d· 2026-04-30

-4.4% · 90d

$12.48

+0.01 (+0.08%)

After-Hours $12.48(+0.00)

News

(1)

April 2026

Apr 20, 20261 week agoDEF 14AHealthcare

NovoCure seeks shareholder vote on 9 million shares for incentives

NVCRNovoCure Ltd

# 📰 What This Document Is This document is a Definitive Proxy Statement (DEF 14A). Think of it as a comprehensive instruction manual for the upcoming Annual General Meeting of Shareholders. This statement is required by the SEC and provides shareholders with all the necessary information needed to

Read summaryView on SEC EDGAR

Key Data

Market Cap$1.45B

Open$12.41

Prev Close$12.47

Day Range$12.32 – $12.70

52W Range$9.82 – $20.06

Volume868,679

P/E (TTM)—

EPS$-1.22

Dividend Yield—

Beta0.82

Profit Margin-20.79%

Revenue Growth8.10%

Price Target$25.07(+100.9%)

Next Earnings2026-04-30(3d)

Analyst Ratings

Strong Buy7 analysts

Buy 5Hold 2Sell 0

About

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Healthcare · Medical Devices

1,605 employees

www.novocure.com